1.3m switched to new ARV, but weight gain is a concern

1.3m switched to new ARV, but weight gain is a concern

Two years after it was announced that the ARV dolutegravir would become part of standard first line HIV treatment in South Africa, it is finally reaching significant numbers of people. But new research about a worrying side-effect, weight gain (particularly in women), has muddied its otherwise stellar reputation.

Read More

IN-DEPTH: Vaginal ring ushers in new era in HIV prevention

IN-DEPTH: Vaginal ring ushers in new era in HIV prevention

A recent announcement about a vaginal ring to prevent HIV has AIDS activists and women’s sexual and reproductive health advocates excited. But where would this ring fit in South Africa’s HIV prevention programme? Amy Green investigates.

Read More

Breakthrough hepatitis C medicines remain in regulatory limbo

Breakthrough hepatitis C medicines remain in regulatory limbo

Over the last decade the treatment of hepatitis C, a virus that can infect and damage the liver, has been revolutionised by a new class of medicines called direct acting antivirals. Catherine Tomlinson investigates the regulatory obstacles that are limiting access to these breakthrough medicines in South Africa.

Read More